GalNAc-siRNA Conjugates for Hepatocyte Targeting
Chemically stabilized synthetic siRNA coupled to a triantennary N-acetylgalactosamine (GalNAc) ligand, targeting the asialoglycoprotein receptor (ASGPR) for subcutaneous gene silencing in hepatic diseases.
1 · What it gives
GalNAc-siRNA conjugates represent the gold standard delivery architecture for hepatocyte-directed RNA interference therapeutics, bypassing the need for complex lipid nanoparticle formulations. The platform couples chemically modified, double-stranded small interfering RNA (typically 21–23 base pairs) to a trivalent branched N-acetylgalactosamine (GalNAc) cluster. This molecular ligand exhibits high affinity (sub-nanomolar avidity) for the asialoglycoprotein receptor (ASGPR, specifically subunits ASGR1 and ASGR2), which is abundantly and uniquely expressed on the sinusoidal membrane of hepatocytes (~500,000 receptors per cell), enabling rapid clathrin-mediated endocytosis.
The therapeutic potency and remarkable longevity (dosing regimens every 3 to 6 months) are driven by comprehensive chemical stabilization of the oligonucleotide backbone. Every ribose sugar is substituted with 2’-O-methyl (2’-OMe) or 2’-deoxy-2’-fluoro (2’-F) modifications arranged in alternating patterns, combined with stereochemically pure phosphorothioate (PS) internucleotide linkages at the terminal positions. Upon receptor-mediated internalization and ASGPR recycling to the plasma membrane, the siRNA escapes endosomes, is cleaved from the GalNAc linker by intracellular esterases, and loads directly into Argonaute-2 (AGO2) within the RNA-induced silencing complex (RISC), triggering catalytic, sequence-specific destruction of target mRNA.
The key directions of this technology are:
- Trivalent GalNAc Dendrimer Engineering: Convergent synthesis of branched triantennary GalNAc phosphoramidites with optimized spatial geometry (inter-galactose distances of 15–20 Å) matching the triangular binding pockets of the ASGPR oligomer.
- Metabolically Stabilized Oligo Chemistries: Implementing ESC (Enhanced Stabilization Chemistry) and next-gen patterns replacing immunogenic 2’-F with 2’-OMe and 5’-(E)-vinylphosphonate (5’-VP) cap analogs for prolonged RISC residence.
- Subcutaneous Auto-Injector Formulation: Aqueous formulation in phosphate-buffered saline (PBS) at high concentrations (>100 mg/mL) with low viscosity (<5 cP), enabling painless, low-volume (1.0–1.5 mL) self-administration.
- Extrahepatic ASGPR-Independent Variants: Adapting the multivalent conjugation chemistry to alternative targeting ligands (e.g., integrin-binding peptides, aptamers) for non-hepatic tissues while preserving the core stabilized siRNA architecture.
Sectoral value chain#
┌────────────────────────────────────────────────────────┐
│ Tier 1: Solid-Phase Automated Phosphoramidite Synth. │
│ (Controlled Pore Glass, 2'-OMe / 2'-F / PS backbones) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 2: Triantennary GalNAc Cluster Solid Coupling │
│ (Solid-support or post-cleavage click / ester ligation)│
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 3: Anion-Exchange & Reverse-Phase Purification │
│ (Preparative AX-HPLC, desalting, >98.5% purity) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 4: Duplex Annealing & Stoichiometric QC │
│ (Sense & antisense equimolar hybridization, LC-MS) │
└───────────────────────────────────┬────────────────────┘
│
▼
┌────────────────────────────────────────────────────────┐
│ Tier 5: Sterile Filtration, Lyophilization & Fill │
│ (0.22 um PES filtration, PBS reconstitution, PFS) │
└────────────────────────────────────────────────────────┘
Value chain levels#
| Level | Description | Key inputs/outputs |
|---|---|---|
| Building Block & Phosphoramidite Synthesis | High-purity chemical synthesis of 2’-modified ribonucleosides, phosphitylation, and triantennary GalNAc branch units. | In: Nucleoside precursors, phosphitylating agents, GalNAc ligand synthons. Out: HPLC-purified phosphoramidites and GalNAc-CPG solid support. |
| Automated Solid-Phase RNA Assembly | Sequential stepwise coupling of sense and antisense strands on large-scale (100–500 mmol) synthesizer columns with DMT deprotection and sulfurization. | In: Phosphoramidites, solid support, activators, sulfurizing reagents. Out: Fully protected, support-bound RNA single strands. |
| Cleavage, Deprotection & Crude Separation | Aqueous ammonia/methylamine treatment to cleave the linker, remove cyanoethyl and base-protecting groups, followed by fluoride desilylation. | In: Crude cleaving reagents, triethylamine trihydrofluoride. Out: Crude aqueous RNA single strands containing GalNAc conjugate. |
| Chromatographic Polishing & Duplex Annealing | Preparative strong anion-exchange (SAX) HPLC and tangential flow filtration (TFF) desalting, followed by controlled thermal duplex annealing. | In: Crude oligo pools, sodium perchlorate buffer, ultrafiltration cassettes. Out: Purified double-stranded GalNAc-siRNA bulk active substance. |
| Sterile Fill-Finish & Analytical Release | Aseptic compounding in PBS (pH 7.4), terminal 0.22 um PES filtration, and automated filling into pre-filled glass syringes (PFS) or vials. | In: Duplex bulk drug substance, excipient buffers, glass syringes. Out: Final commercial injectable drug product meeting USP <788> standards. |
Cross-cutting technologies of the sector:
- Process Analytical Technology (PAT) in Oligo Synthesis: In-line UV-Vis trityl monitoring and real-time conductivity sensing verifying coupling efficiency (>99.2% per cycle).
- High-Resolution Orbitrap LC-MS Deconvolution: Exact mass verification of full-length oligo sequences and characterization of n-1 deletion and phosphorothioate stereoisomer impurities.
2 · What it replaces 0 · matched by industry
No graded substitution linked yet.
3 · How to implement 4 steps
- 1Triantennary GalNAc ligand synthesisConvergent synthesis of branched trivalent GalNAc clusters optimized for sub-nanomolar ASGPR avidity.
- 2Phosphoramidite oligonucleotide synthesisAutomated RNA solid-phase synthesis with 2’-OMe, 2’-F, and phosphorothioate stability modifications.
- 3Subcutaneous formulationFormulating aqueous, sterile, room-temperature stable injectable solutions without lipid excipients.
- 4Durable hepatic mRNA knockdownAchieving up to 6 months of sustained target mRNA and protein suppression in liver tissue per single dose.
4 · Who delivers
Matched suppliers (matched automatically)
| Novartis | Switzerland | Producer | active |
| Lonza Group | Switzerland | Producer | active |
| GSK | United Kingdom | Producer | active |
| Jiangsu Hengrui Medicine | China | Producer | active |
| Daiichi Sankyo | Japan | Producer | active |
| Bluestem Biosciences | United States | Producer | active |
| Global Bioenergies | France | Producer | active |
| Haesin | South Korea | Research / RTO | active |
| PUEVIT GmbH | Germany | Equipment | active |
Leading companies and institutes (from the brief)
| Company / Institute | Country | Key products / platforms | Tech features | Status 2026 |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | 🇺🇸 United States | Givlaari, Oxlumo, Amvuttra | Pioneer of ESC GalNAc-siRNA platform | commercial |
| Novartis | 🇨🇭 Switzerland | Leqvio (inclisiran) | Biannual PCSK9 siRNA for hyperlipidemia | commercial |
| Silence Therapeutics | 🇬🇧 United Kingdom | Zerlasiran (SLN360), Divesiran | Proprietary mRNAi GOLD GalNAc platform | clinical |
| Sirnaomics | 🇺🇸 United States | STP122G, GalNAc platforms | Dual-targeting siRNA conjugates for liver fibrosis | clinical |
| Suzhou Ribo Life Science | 🇨🇳 China | RBD7022, RIBO-GalSTAR | Leading Chinese clinical GalNAc platform | clinical |
| Bachem | 🇨🇭 Switzerland | Commercial Oligo API Manufacturing | Large-scale solid-phase synthesizer suites | commercial |
| CordenPharma | 🇩🇪 Germany | Oligo & Conjugation CDMO | Integrated lipid, peptide, and GalNAc synthesis | commercial |
5 · Rules & route to market
United States
Commercial leadership, cardiovascular and rare disease pipelines#
- FDA Regulatory Milestones: FDA approvals of Givlaari (givosiran), Oxlumo (lumasiran), Leqvio (inclisiran), and Amvuttra (vutrisiran) established the CDER regulatory approval roadmap under 505(b)(1) NDA pathways.
- Mass-Market Indications: Transition from ultra-rare hepatic diseases to high-prevalence cardiovascular indications (e.g., hypercholesterolemia, Lp(a) lowering, hypertension via angiotensinogen targeting).
- Manufacturing Infrastructure: Large-scale automated synthesis facilities operating in Colorado, Massachusetts, and North Carolina capable of multi-hundred-kilogram annual synthetic oligo output.
European Union
Swiss and European CMO powerhouses, EMA PRIME designations#
- Contract CDMO Scaling: Global contract manufacturing hubs (Lonza in Visp/Basel, Bachem in Bubendorf, CordenPharma) driving multi-ton peptide and oligonucleotide synthesis capabilities.
- EMA Approval Precedents: Successful centralized marketing authorizations across all 27 EU member states with streamlined post-authorization safety monitoring (PASS).
- Green Chemistry Initiatives: European consortiums developing eco-friendly peptide/oligo coupling reagents that replace toxic N,N-dimethylformamide (DMF) with bio-based green solvents (2-MeTHF, Cyrene).
China
Rapid biosimilar and novel target expansion, NMPA fast-track#
- NMPA Priority Review Status: Domestic biopharmas leveraging China’s Center for Drug Evaluation (CDE) priority review channels for hepatic target pipelines (HBV clearance, hyperlipidemia, PCSK9/ANGPTL3).
- Regional Oligo Manufacturing Hubs: High-capacity solid-phase synthesis and reagent clusters established across Jiangsu (Suzhou BioBAY) and Shanghai Zhangjiang Hi-Tech Park.
- Clinical Breakthroughs in HBV: State-funded National Science and Technology Major Projects backing novel GalNAc-siRNA conjugates achieving sustained HBsAg seroclearance in chronic hepatitis B patients.
6 · Money: tenders & grants
No open tender or grant matched right now.
7 · Tech stack & innovations
- Triantennary GalNAc Cluster Scaffolding:
- Utilizes tris-hydroxymethyl aminomethane (TRIS) or branched pentaerythritol cores linked via hydrophilic PEG or alkyl spacers to 3 terminal alpha-D-GalNAc residues.
- Optimized spatial geometry achieves sub-nanomolar dissociation constants (Kd = 0.1–1.0 nM) for hepatic ASGPR complexes.
- Enhanced Stabilization Chemistry (ESC):
- Comprehensive alternating 2’-OMe / 2’-F chemical modification motifs eliminating endo- and exo-nuclease degradation in serum.
- Stereochemically configured terminal phosphorothioate internucleotide bonds protecting terminal ends from exonucleolytic degradation.
- In-Line PAT & Solid-Phase Synthesizers:
- Automated high-pressure flow-through synthesizers with dynamic axial compression (DAC) columns operating at pressures up to 100 bar.
- Conductometric trityl monitoring providing real-time feedback and closed-loop control of deblocking, coupling, and capping cycles.
Sources 1 · 0 independent · 1 producer sites
Producers' own sites 1
- www.swissbiotech.org producer checked 2026-11-22